WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > ViaGen
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Industry Outlook
Globenewswire | May 29, 2023
Monte Rosa Therapeutics, Inc. a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases. “MRT-6160 is a potent, orally bioavai...
Cell and Gene Therapy, Industrial Impact
Globenewswire | May 02, 2023
Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...
Industrial Impact
Cellics Therapeutics | September 13, 2022
Cellics Therapeutics, Inc., a biotechnology company pioneering Cellular Nanoparticle platform technology for drug development and delivery, announced today that the company has appointed Paul Daruwala as the company's president and chief executive officer, effective on October 1st, 2022. With 30 years of experience in biotech drug development, Daruwala brings a depth of vision, as well as start-up and operational experience to Cellics. "With our Cellular Nanoparticle plat...
ImmunoGen, Inc. | March 02, 2023
On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...
Medical, Industry Outlook
Whitepaper
Cell and Gene Therapy, Medical
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE